MaxCyte Inc logo

MXCT - MaxCyte Inc News Story

410p -8.0  -1.9%

Last Trade - 23/10/20

Sector
Healthcare
Size
Small Cap
Market Cap £276.4m
Enterprise Value £250.9m
Revenue £18.5m
Position in Universe 677th / 1805

RCS - MaxCyte, Inc. - HC Wainright & Co Virtual Conference Presentation

Thu 10th September, 2020 7:00am
For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200910:nRSJ5403Ya

RNS Number : 5403Y  MaxCyte, Inc.  10 September 2020

 

 

MaxCyte to Present at Upcoming 2020 H.C. Wainright & Co

22nd Annual Global Investment Virtual Conference

 

 

GAITHERSBURG, MD, 10 September 2020 - MaxCyte, Inc. (LSE: MXCT, MXCL), a
global cell-based therapies and life sciences company, today announced that
CEO Doug Doerfler plans to present an overview of the company at the upcoming
H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference
taking place September 14-16, 2020.  Details are as follows:

 

Presentation Date/Time: Monday, September 14, at 4:00 p.m. EDT

Online access: https://wsw.com/webcast/hcw7/maxcyte/2019107
(https://wsw.com/webcast/hcw7/maxcyte/2019107)

 

 

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences
company. As the inventors of the premier cell-engineering enabling technology,
the Company helps bring the promise of next-generation cell and gene-editing
therapies to life. The Company's technology is currently being deployed by
leading drug developers worldwide, including all of the top ten global
biopharmaceutical companies. MaxCyte licences have been granted for more than
120 cell therapy programmes, with more than 90 licensed for clinical use, and
the Company has now entered into eleven clinical/commercial license
partnerships with leading cell therapy and gene editing developers. MaxCyte
was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL)
and is headquartered in Gaithersburg, Maryland, US. For more information,
visit  www.maxcyte.com (http://www.maxcyte.com)  .

 

 

  Contacts:

 

 MaxCyte Inc.                                                     +1 301-944-1660

 Doug Doerfler, Chief Executive Officer

 Amanda Murphy, Chief Financial Officer

 Nominated Adviser and Joint Corporate Broker

 Panmure Gordon                                                   +44 (0)20 7886 2500

 Emma Earl

 Freddy Crossley

 Corporate Broking

 Rupert Dearden

 Joint Corporate Broker

 Numis Securities Limited                                         +44 (0)20 7260 1000

 James Black

 Duncan Monteith

 Financial PR Adviser                                             +44 (0)203 709 5700

 Consilium Strategic Communications                               maxcyte@consilium-com

 Mary-Jane Elliott

 Chris Welsh

 Ashley Tapp

 --------------------------------------------------------------

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Private Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKKCBNOBKDBCK
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.